Ibogaine & alcohol use disorder

Research & Resources

A practical starting point for reading studies, trial records, safety reports, and official information about ibogaine in relation to alcohol use disorder.

Use this page carefully

A study, a registry entry, or a promising headline is not the same thing as established care.

This collection is scoped to ibogaine and alcohol use disorder. It is designed to help people living with alcohol use disorder, and those supporting them, distinguish early signals from settled conclusions. For the broader evidence-and-risk frame used across this site, start with the ibogaine and alcohol use disorder overview; the resource principles behind this work explain why independence and plain language matter here.

Studies to place in context

What the published record can—and cannot—tell you.

The available human literature is limited, often observational, and commonly focused on substance use conditions other than alcohol use disorder. Read methods, participant selection, co-occurring care, follow-up, and adverse-event reporting alongside the outcome claims.

Observational evidence

Psychedelic-treatment observational cohorts

Published work from non-randomized settings can describe what happened among participants, but it cannot by itself show that ibogaine caused an alcohol-related outcome. Observational designs are vulnerable to selection effects, missing follow-up, concurrent interventions, and incomplete safety capture. The PubMed research index is useful for checking the original abstract, authors, and publication record rather than relying on summaries.

Early-phase human research

Small studies are not confirmation

Early human studies may explore dosing, short-term tolerability, or feasibility. They are generally not designed to establish effectiveness for alcohol use disorder. When reviewing any early-phase result, look for the population studied and whether alcohol use disorder was actually the condition under investigation.

Noribogaine development

A related compound is not interchangeable evidence

Noribogaine is a metabolite of ibogaine and has been investigated separately in drug-development contexts. Evidence about a related compound should not be treated as direct evidence for ibogaine in people living with alcohol use disorder. The background pharmacology of ibogaine can help orient terminology, but it does not replace study-level review.

Registries & development

Check the public record before interpreting a trial claim.

A registration can show how researchers described a study at a particular time. It does not confirm outcomes, safety, eligibility for an individual, or availability of treatment.

Clinical trial registrations

Use the registry as a primary source

ClinicalTrials.gov records for ibogaine can be searched for listed studies, stated aims, recruitment status, and posted results where available. A record may change over time; “recruiting” or “completed” does not itself establish a result or a recommendation.

Regulatory milestones

Development activity is not approval

In the United States, the FDA’s information on ibogaine is an important reference point for legal and safety context. Regulatory pathways, research permissions, and public discussion of a compound should not be mistaken for authorization of ibogaine as a treatment for alcohol use disorder.

Reading the timeline

Record dates and endpoints

For any cited trial, note the first posting date, the last update, the prespecified outcome measures, and whether results were posted. This helps separate a preliminary research plan from published, peer-reviewed findings.

Safety case reports & guidance

Risk information belongs beside every efficacy discussion.

Case reports and safety reviews are especially relevant because ibogaine has been associated with serious cardiac risks, including changes to heart rhythm. A research result about substance-use outcomes does not cancel the importance of medical screening, medication interactions, electrolyte concerns, or the risks associated with alcohol withdrawal.

Important: Alcohol withdrawal can be medically dangerous. This resource hub is not a substitute for urgent medical care, individualized assessment, or local emergency services.

A steadier way to read

Keep claims tied to their source.

High-quality reading means returning to source documents and retaining uncertainty where uncertainty remains.

Start with the abstract and full paper when available. Identify whether the report concerns alcohol use disorder directly, whether the design is randomized or observational, and whether adverse events are described. Then compare what a source says with the carefully limited explanations in how ibogaine mechanisms are discussed in AUD.

Safety reports deserve the same attention as outcome reports. The NCBI Bookshelf overview of adverse drug reactions offers general context for why adverse-event reporting matters when evaluating any medication or investigational compound.

Legal status differs by country and can change. This page does not provide legal advice, treatment referrals, recruitment, or clinic listings. It is an information resource for people trying to read the record more carefully.

Questions to keep asking

Before you draw a conclusion.

Does this page recommend ibogaine for alcohol use disorder?

No. This page is for information only. It does not offer treatment referrals or medical advice, and it does not establish that ibogaine is safe or effective for alcohol use disorder.

Where can clinical trial registrations be checked?

ClinicalTrials.gov is a public registry and results database. A registration can clarify a study’s stated purpose, eligibility, location, and status, but registration does not establish that a treatment is safe, effective, or available.

What should be considered alongside research findings?

Consider the safety concerns, legal status, study limitations, and the need for individualized medical assessment. Alcohol withdrawal can itself be medically dangerous, so urgent or withdrawal-related concerns need appropriate medical attention.

Keep the context in view

Evidence is only useful when risks are kept in the frame.

Review safety considerations